Screener
BioMarin Pharmaceuticals BMRN Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 114,049 | 40,632 |
| Non-cash interest expense | 27,912 | 1,320 |
| Stock-based compensation | 119,152 | 85,231 |
| Impairment of assets | — | 2,967 |
| Deferred income taxes | 2,261 | 61,771 |
| Unrealized foreign exchange gains | (4,046) | (5,306) |
| Other | (5,534) | (4,633) |
| Changes in operating assets and liabilities, net of effects of business acquired: |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's impairment charges?
- BioMarin Pharmaceuticals (BMRN) reported impairment charges of $0 in Q2 2026.
- What does impairment charges mean?
- Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.
Ask your AI about BioMarin Pharmaceuticals's impairment charges.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude